209526-91-0

Basic information

• Product Name: 2-(BroMoMethyl)-5-Methoxypyridine
• Synonyms: 2-(BroMoMethyl)-5-Methoxypyridine
• CAS NO: 209526-91-0
• Molecular Weight: 202.04852
• Mol File: 209526-91-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(BroMoMethyl)-5-Methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BroMoMethyl)-5-Methoxypyridine(209526-91-0)
• EPA Substance Registry System: 2-(BroMoMethyl)-5-Methoxypyridine(209526-91-0)

Safety Data

• Hazardous Substances Data: 209526-91-0(Hazardous Substances Data)

Usage

General Description

2-(Bromomethyl)-5-methoxypyridine is a chemical compound with the formula C7H8BrNO. It is a yellowish liquid that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is a derivative of pyridine and contains a bromomethyl group and a methoxyl group, making it useful in organic synthesis for various applications. It is important to handle this compound with caution as it may be harmful if inhaled, swallowed, or in contact with skin, and should be kept away from sources of ignition.

Upstream product

• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 55270-47-8 5-methoxy-2-picoline 
• 127978-70-5 2-hydroxymethyl-5-methoxypyridine 

Downstream Products

• 1453500-46-3 1-(2-(4-((dimethylamino)methyl)-2-methylphenyl)-2-oxoethyl)-4-((5-methoxypyridin-2-yl)methoxy)pyridin-2(1H)-one 
• 1453500-22-5 1-[2-(4-hydroxymethyl-2-methyl-phenyl)-2-oxo-ethyl]-4-(5-methoxy-pyridin-2-ylmethoxy)-1H-pyridin-2-one 
• 1453500-23-6 1-[2-(4-bromomethyl-2-methyl-phenyl)-2-oxo-ethyl]-4-(5-methoxy-pyridin-2-ylmethoxy)-1H-pyridin-2-one 

Relevant articles and documents

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of general formula I, wherein the groups R1, R2, L1, L2, U and B are as defined in the application, which have valuable pharmacological properties, and in particular modulate the activity of the MCH receptor.

5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor

The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.